News

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...
360Dx4d
Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda
The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.
Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...
Barchart on MSN5d
What to Expect From Regeneron's Next Quarterly Earnings Report
With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...
Regeneron: Still A Biotech Juggernaut
Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...